Early studies of etoposide phosphate, a water-soluble prodrug.

Abstract:

:Etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) is a water-soluble prodrug of etoposide that is converted in vivo by endogenous phosphatases to the active drug etoposide. This conversion process is efficient and not saturable in humans at doses between 50 and 1,600 mg/m2. The resultant etoposide demonstrates classic pharmacokinetics, and the etoposide phosphates dose is linearly related to peak levels and the area under the concentration-time curve of etoposide. The absence of noxious solvents and the ability to administer the drug in small volumes over short periods make etoposide a phosphate attractive for conventional- and high-dose clinical programs.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Budman DR

subject

Has Abstract

pub_date

1996-12-01 00:00:00

pages

8-14

issue

6 Suppl 13

eissn

0093-7754

issn

1532-8708

journal_volume

23

pub_type

杂志文章,评审
  • Adjuvant chemotherapy for breast cancer: an update.

    abstract::Adjuvant chemotherapy in breast cancer has clearly been shown to reduce mortality. The benefits extend to pre- and postmenopausal women and those with node-negative, node-positive, estrogen receptor (ER)-positive, and ER-negative disease. Updated data regarding chemoendocrine therapy in postmenopausal women and anthra...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90130-7

    authors: Tan AR,Swain SM

    更新日期:2001-08-01 00:00:00

  • Measuring quality of life: an emerging science.

    abstract::Quality of life (QOL) variables are increasingly included as end points in cancer therapy trials, supplementing such traditional end points as survival time in evaluating the effects of cancer treatments. Consensus has been reached that a number of QOL components (symptom status and physical, emotional, role, and soci...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Moinpour CM

    更新日期:1994-10-01 00:00:00

  • Immune tolerance and transplantation.

    abstract::Successful allogeneic hematopoietic stem cell transplantation (HSCT) and solid organ transplantation require development of a degree of immune tolerance against allogeneic antigens. T lymphocytes play a critical role in allograft rejection, graft failure, and graft-versus-host disease (GVHD). T-cell tolerance occurs b...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.10.001

    authors: Alpdogan O,van den Brink MR

    更新日期:2012-12-01 00:00:00

  • Single agents in the second-line treatment of non-small cell lung cancer.

    abstract::The options available to patients with advanced non-small cell lung cancer (NSCLC) resistant or refractory to first-line chemotherapy are very limited. The older-generation drugs (etoposide, vindesine, epirubicin, and cisplatin) that are active against previously untreated NSCLC do not achieve a response rate greater ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Belani CP

    更新日期:1998-06-01 00:00:00

  • Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study.

    abstract::The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7-week total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) combined with standard curative radiotherapy (RT) for pre...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rosenthal DI,Sinard RJ,Okani O,Corak J,Kavanaugh D,Kamen B,Vuitch FM,Gazdar AF,Griener J,Frenkel EP,Carbone DP

    更新日期:1997-12-01 00:00:00

  • The interface between medical oncology and supportive and palliative cancer care.

    abstract::Traditionally, medical oncology has focused on the active period of diagnosis, treatment and follow-up of cancer patients, and palliative medicine, the pre-terminal and end-of-life phases. Palliative medicine physicians have particular expertise in communication and symptom control, especially, for example, with pain ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2011.03.021

    authors: Storey DJ,Fallon MT,Smyth JF

    更新日期:2011-06-01 00:00:00

  • Advances in the biology of multiple myeloma: therapeutic applications.

    abstract::Recent advances in the biology of multiple myeloma cell growth and survival have suggested new avenues for treatment and potential cure of this disease. Adhesion molecules on the myeloma cell surface mediate their localization in the bone marrow via binding to extracellular matrix proteins and stromal cells. Stromal c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Anderson K

    更新日期:1999-10-01 00:00:00

  • Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.

    abstract::Immune dysregulation, a hallmark of chronic lymphocytic leukemia (CLL), manifests itself in three autoimmune diseases: warm autoimmune hemolytic anemia (AIHA); idiopathic thrombocytopenia (ITP); and, pure red cell aplasia (PRCA). AIHA occurs in 11% of advanced stage CLL patients. Prednisone is the first treatment of c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Diehl LF,Ketchum LH

    更新日期:1998-02-01 00:00:00

  • In vitro data supporting interferon plus cytotoxic agent combinations.

    abstract::The human tumor cloning system is an in vitro assay that has been used to predict response of patients' tumors to conventional antineoplastic agents as well as to biologic agents. In addition, the assay has been used to screen for antitumor activity of newly discovered cytotoxics and biologics. The purpose of the pres...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Von Hoff DD

    更新日期:1991-10-01 00:00:00

  • Transfusion support in acute leukemias.

    abstract::Patients with acute myeloid leukemia and acute lymphocytic leukemia receive significant numbers of blood products for hematologic support during periods of disease and treatment related cytopenias. These patients may be at increased risk for complications associated with transfusion. This article reviews the indicatio...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Webb IJ,Anderson KC

    更新日期:1997-02-01 00:00:00

  • Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated substantial single-agent activity against both minimally pretreated and resistant metastatic breast cancer. Evaluation of paclitaxel-based combinations has demonstrated appreciable activity, but also toxicity, for the paclitaxel/doxorubic...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kennedy MJ,Donehower RC,Rowinsky EK

    更新日期:1995-08-01 00:00:00

  • Tools of the trade to address schooling related communication needs after childhood cancer: A mini-review with consideration of health disparity concerns.

    abstract::Over the last 60 years, success rates in treating childhood cancers have grown dramatically from 10% to greater than 85%. Negative effects of treatments, however, place survivors at risk for neurocognitive deficits that can make school challenging. Evidence shows that receiving special education services can benefit a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1053/j.seminoncol.2020.02.003

    authors: Paré-Blagoev EJ,Ruble K,Jacobson LA

    更新日期:2020-02-01 00:00:00

  • Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.

    abstract::Combination antimicrotubule therapy with estramustine phosphate (EMP) and vinblastine has reproducible activity in metastatic hormone-refractory prostate cancer (HRPC) with an objective response rate of 31%. Although paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 24-hour infusion was inactive in HR...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hudes GR,Nathan FE,Khater C,Greenberg R,Gomella L,Stern C,McAleer C

    更新日期:1995-10-01 00:00:00

  • Cooperative Group Trials in the Community Setting.

    abstract::Over the last 40 years the National Cancer Institute (NCI) has created a vibrant public-private partnership for the implementation of NCI-sponsored cooperative group (Network) clinical trials throughout the United States and Canada. Over these four decades, the cancer clinical trials process has become more complex mo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.07.011

    authors: Lloyd Wade J 3rd,Petrelli NJ,McCaskill-Stevens W

    更新日期:2015-10-01 00:00:00

  • Richter syndrome: pathogenesis and management.

    abstract::Richter syndrome (RS) is the development of an aggressive lymphoma in patients with a previous or concomitant diagnosis of chronic lymphocytic leukemia (CLL). The incidence rate RS is ~0.5% per year of observation. Two biomarkers (NOTCH1 mutations and subset 8 configuration of the B-cell receptor) may help identifying...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.02.012

    authors: Rossi D,Gaidano G

    更新日期:2016-04-01 00:00:00

  • Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.

    abstract::Gastrointestinal stromal tumor (GISTs) are the most common connective tissue malignancies of the gastrointestinal (GI) tract, with an incidence on the order of 10-13 per million people per year. Primary therapy is usually surgical, but the recurrence rate of large, so-called high-risk tumors, with a high mitotic rate,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2009.06.002

    authors: Reichardt P,Hogendoorn PC,Tamborini E,Loda M,Gronchi A,Poveda A,Schöffski P

    更新日期:2009-08-01 00:00:00

  • Management of early and locally advanced cervical cancer.

    abstract::Cervical cancer is the second most common malignancy in women and the third most common cause of cancer mortality worldwide. While primary and secondary preventions exist, the lack of widespread adoption leaves the treatment of cervical cancer an important oncologic problem. In this article, the management of early an...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.12.007

    authors: Barbera L,Thomas G

    更新日期:2009-04-01 00:00:00

  • Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.

    abstract::A phase II study was performed to investigate the tolerance and efficacy of the combination of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) and gemcitabine in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC). To date, 24 patients (five with stage IIIB and 19 with stage IV NSCLC...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Georgoulias V,Kourousis C,Androulakis N,Kakolyris S,Dimopoulos MA,Bouros D,Papadimitriou C,Hatzakis K,Heras P,Kalbakis K,Kotsakis T,Vardakis N,Meramveliotakis N,Hatzidaki D

    更新日期:1997-08-01 00:00:00

  • Hematopoietic growth factors in myelodysplastic syndromes.

    abstract::Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite the advent of disease-modifying therapies for MDS (eg, azacitidine, decitabine, and lenalidomide) and the current absence of an MDS-specific US Food and Drug Adm...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.04.014

    authors: Steensma DP

    更新日期:2011-10-01 00:00:00

  • Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.

    abstract::Non-platinum combination regimens have been developed for advanced non--small cell lung cancer using the novel and active agents docetaxel, gemcitabine, vinorelbine, and irinotecan. The aim of these combinations is to equal or exceed the survival benefits achieved with cisplatin doublets while minimizing toxicity. Of ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Rigas JR

    更新日期:2001-06-01 00:00:00

  • The new staging system for cutaneous melanoma in the era of lymphatic mapping.

    abstract::In 2002, the American Joint Committee on Cancer (AJCC) revised the staging system for cutaneous melanoma on the basis of a survival analysis of important melanoma prognostic factors. Features of the revised system include new strata for primary tumor thickness, incorporation of primary tumor ulceration as an important...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.03.018

    authors: Rousseau DL Jr,Gershenwald JE

    更新日期:2004-06-01 00:00:00

  • Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.

    abstract::Phase I trials of the intraperitoneal (IP) administration of cisplatin have demonstrated that the drug can be safely delivered by this route with a major increase in exposure (approximately tenfold to 15-fold) of the cavity to the cytotoxic agent compared with that of the systemic circulation. Phase I trials of IP cis...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Markman M

    更新日期:1989-08-01 00:00:00

  • Toxicity patterns with immunomodulating antibodies and their combinations.

    abstract::Immune checkpoint molecules cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), but also LAG-3 and TIM-3, are involved in regulation of peripheral tolerance in order to prevent autoimmunity. Blocking of these cell surface proteins by antibodies has resulted in remarkable anti-tumor immunity; howev...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.02.011

    authors: Haanen JB,Thienen Hv,Blank CU

    更新日期:2015-06-01 00:00:00

  • Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer.

    abstract::Lung cancer is the number one cause of cancer-related death in both men and women in the United States. Non-small cell lung cancer accounts for approximately 85% of these cases. Despite complete resection, long-term survival for patients with operable disease remains poor. Studies exploring postoperative chemotherapy ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90056-9

    authors: Pisters KM

    更新日期:2001-08-01 00:00:00

  • Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure.

    abstract::The median latency of 2 degrees MDS/AL is 4 to 5 years. A high percentage of patients with 2 degrees MDS/AL convert to 2 degrees AL. Survival of either is less than 1 year. A constellation of morphologic abnormalities from all 3 cell lines produces a unique appearance. Both 2 degrees MDS and 2 degrees AL are difficult...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Levine EG,Bloomfield CD

    更新日期:1992-02-01 00:00:00

  • Surgical treatment for gastric cancer: the Japanese approach.

    abstract::Present status of gastric cancer surgery in Japan and several new procedures are reviewed in this article. Japanese treatment results of this disease were significantly better than Western results even when stages were adjusted. Generally speaking, Japanese surgical procedures are more aggressive and meticulous compar...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Maruyama K,Sasako M,Kinoshita T,Sano T,Katai H

    更新日期:1996-06-01 00:00:00

  • Clinical experience with denileukin diftitox (ONTAK).

    abstract::Denileukin diftitox (ONTAK; Seragen Inc, San Diego, CA) is a fusion protein designed to direct the cytocidal action of diphtheria toxin to cells that overexpress the IL-2 receptor. The human IL-2 receptor exists in three isoforms: low (CD25), intermediate (CD122/CD132), and high (CD25/CD122/CD132) affinity. The high-a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.12.017

    authors: Foss F

    更新日期:2006-02-01 00:00:00

  • Clinical trials with ifosfamide: the Indiana University experience.

    abstract::At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity--testicular cancer and smal...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Loehrer PJ,Williams SD,Nichols CR,Einhorn LH

    更新日期:1992-02-01 00:00:00

  • Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?

    abstract::A wide variety of cytogenetic abnormalities and molecular pathways have been implicated in the pathogenesis of sarcoma, and significant progress has been made in the past decade toward identifying potential therapeutic targets. However, apart from gastrointestinal stromal tumors (GISTs) and dermatofibrosarcoma protube...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.09.003

    authors: Riedel RF

    更新日期:2011-10-01 00:00:00

  • An overview of HER2.

    abstract::HER2 is a transmembrane growth factor receptor found in normal and malignant breast epithelial cells. Phosphorylation of the intracellular tyrosine kinase results in intracellular signaling and activation of genes involved in cell growth. Overexpression of HER2 has independent prognostic significance in early breast c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Lohrisch C,Piccart M

    更新日期:2001-12-01 00:00:00